These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38330136)

  • 21. Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy.
    Zeng J; Ding X; Ding J; Wang X
    Front Immunol; 2023; 14():1275957. PubMed ID: 38022621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Origins, genetic landscape, and emerging therapies of small cell lung cancer.
    Semenova EA; Nagel R; Berns A
    Genes Dev; 2015 Jul; 29(14):1447-62. PubMed ID: 26220992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs.
    Lin CA; Yu SL; Chen HY; Chen HW; Lin SU; Chang CC; Yu CJ; Yang PC; Ho CC
    J Thorac Oncol; 2019 Mar; 14(3):513-526. PubMed ID: 30521971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
    Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
    Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer.
    Hao L; Chen H; Wang L; Zhou H; Zhang Z; Han J; Hou J; Zhu Y; Zhang H; Wang Q
    Thorac Cancer; 2023 Apr; 14(11):1036-1041. PubMed ID: 36810856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Club cells employ regeneration mechanisms during lung tumorigenesis.
    Chen Y; Toth R; Chocarro S; Weichenhan D; Hey J; Lutsik P; Sawall S; Stathopoulos GT; Plass C; Sotillo R
    Nat Commun; 2022 Aug; 13(1):4557. PubMed ID: 35931677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lineage-restricted neoplasia driven by Myc defaults to small cell lung cancer when combined with loss of p53 and Rb in the airway epithelium.
    Chen J; Guanizo A; Luong Q; Jayasekara WSN; Jayasinghe D; Inampudi C; Szczepny A; Garama DJ; Russell PA; Ganju V; Cain JE; Watkins DN; Gough DJ
    Oncogene; 2022 Jan; 41(1):138-145. PubMed ID: 34675406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex.
    Llabata P; Torres-Diz M; Gomez A; Tomas-Daza L; Romero OA; Grego-Bessa J; Llinas-Arias P; Valencia A; Esteller M; Javierre BM; Zhang X; Sanchez-Cespedes M
    Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34493659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer.
    Udyavar AR; Hoeksema MD; Clark JE; Zou Y; Tang Z; Li Z; Li M; Chen H; Statnikov A; Shyr Y; Liebler DC; Field J; Eisenberg R; Estrada L; Massion PP; Quaranta V
    BMC Syst Biol; 2013; 7 Suppl 5(Suppl 5):S1. PubMed ID: 24564859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer.
    Grzeskowiak CL; Kundu ST; Mo X; Ivanov AA; Zagorodna O; Lu H; Chapple RH; Tsang YH; Moreno D; Mosqueda M; Eterovic K; Fradette JJ; Ahmad S; Chen F; Chong Z; Chen K; Creighton CJ; Fu H; Mills GB; Gibbons DL; Scott KL
    Nat Commun; 2018 Jul; 9(1):2732. PubMed ID: 30013058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bromodomain and hedgehog pathway targets in small cell lung cancer.
    Kaur G; Reinhart RA; Monks A; Evans D; Morris J; Polley E; Teicher BA
    Cancer Lett; 2016 Feb; 371(2):225-39. PubMed ID: 26683772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
    PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exosomal lncRNA FOXD3-AS1 upregulates ELAVL1 expression and activates PI3K/Akt pathway to enhance lung cancer cell proliferation, invasion, and 5-fluorouracil resistance.
    Mao G; Mu Z; Wu DA
    Acta Biochim Biophys Sin (Shanghai); 2021 Nov; 53(11):1484-1494. PubMed ID: 34605863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterogeneity or transformation? A whack-a-mole case of EGFR-mutant lung adenocarcinoma and small cell carcinoma: A case report.
    Ninomaru T; Hata A; Hara S; Komatsu M
    Thorac Cancer; 2022 Aug; 13(16):2394-2397. PubMed ID: 35793695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer.
    Huang F; Huffman KE; Wang Z; Wang X; Li K; Cai F; Yang C; Cai L; Shih TS; Zacharias LG; Chung A; Yang Q; Chalishazar MD; Ireland AS; Stewart CA; Cargill K; Girard L; Liu Y; Ni M; Xu J; Wu X; Zhu H; Drapkin B; Byers LA; Oliver TG; Gazdar AF; Minna JD; DeBerardinis RJ
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33079728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different pattern of expression of cellular oncogenes in human non-small-cell lung cancer cell lines.
    Kiefer PE; Wegmann B; Bacher M; Erbil C; Heidtmann H; Havemann K
    J Cancer Res Clin Oncol; 1990; 116(1):29-37. PubMed ID: 1690210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TRIP13 promotes lung cancer cell growth and metastasis through AKT/mTORC1/c-Myc signaling.
    Cai W; Ni W; Jin Y; Li Y
    Cancer Biomark; 2021; 30(2):237-248. PubMed ID: 33136091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transformation from EGFR/PTEN co-mutated lung adenocarcinoma to small cell carcinoma in lymph node metastasis.
    Hayashi T; Takamochi K; Kohsaka S; Kishikawa S; Suehara Y; Takahashi F; Suzuki K; Saito T; Yao T
    Pathol Int; 2020 May; 70(5):295-299. PubMed ID: 32162763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.